-
Leptin (116-130), amide, mouse: Workflows
2026-08-19
Leptin (116-130), amide, mouse supports controlled studies of metabolic signaling, immune crosstalk, and leptin resistance without relying on an undefined biological mixture. This applied guide covers preparation, assay design, reference-informed pathway testing, and troubleshooting for obesity and diabetes research.
-
BMP4–GPX4 Protects RGCs in NMDA Glaucoma Models
2026-08-19
Fang and colleagues identify the BMP4–GPX4 axis as a potential regulator of ferroptosis and retinal stem cell performance in an NMDA-based mouse glaucoma model. Their findings connect reduced oxidative and iron stress in retinal ganglion cells with improved conditions for retinal stem cell survival and differentiation, while also highlighting important limits of translating an excitotoxic injury model to human glaucoma.
-
Nicotine Signaling and CKD Progression: Study Review
2026-08-18
Jain and Jaimes integrate clinical and experimental evidence showing that nicotine may accelerate chronic kidney disease through kidney-expressed nicotinic acetylcholine receptors, oxidative stress, hemodynamic changes, and pro-fibrotic signaling. The review’s main practical contribution is a mechanistic framework for interpreting smoking-related renal injury and designing studies that distinguish nicotine effects from the broader toxicity of cigarette smoke.
-
Phosphatase Inhibitor Cocktail 2: Workflow Guide
2026-08-18
Phosphatase Inhibitor Cocktail 2 is a 100X aqueous reagent for protein phosphorylation preservation in crude extracts. Its broad formulation supports inhibition of tyrosine, acid, and alkaline phosphatases, while the cited liver-stress study shows why phosphoprotein handling matters for AMPK and p38 MAPK analysis.
-
c-Myc Tag Peptide: Mechanism and Use
2026-08-17
The c-Myc tag peptide A6003 is a synthetic C-terminal c-Myc fragment used for displacement of c-Myc-tagged fusion proteins from anti-c-Myc antibodies. Its defined molecular weight, high purity, solvent-specific solubility, and storage guidance support controlled immunoassay development rather than direct pharmacological inhibition of cellular MYC.
-
(5Z)-7-Oxozeaenol: Map TAK1 in Stress
2026-08-17
(5Z)-7-Oxozeaenol is a selective TAK1 inhibitor for separating inflammatory signaling from metabolic-stress adaptation. This guide connects TAK1-dependent p62 phosphorylation with AMPK–NRF2 feedback and translates that biology into more discriminating assay designs.
-
Calpain Inhibitor II, ALLM: Protease Workflow Guide
2026-08-16
Calpain Inhibitor II, ALLM enables cell-based apoptosis studies and controlled protease inhibition assays while also helping researchers test calpain-dependent protein cleavage. This guide connects practical dosing, FAK-proteolysis workflows, and troubleshooting for leukemia, lymphoma, and breast cancer models.
-
AR Heterogeneity and Enzalutamide Response in Prostate Cance
2026-08-15
Li et al. show that androgen receptor expression heterogeneity is functionally linked to distinct castration and enzalutamide responses in castration-resistant prostate cancer. By combining patient tissue profiling, xenografts, genome-edited LNCaP clones, transcriptomics, and combination treatment studies, the authors identify BCL-2 as a potential vulnerability across biologically distinct tumor states.
-
Curcumol, KAT8, and Necroptosis in Liver Fibrosis
2026-08-14
A 2026 International Journal of Biological Sciences study identifies a lactate–KAT8–HK2 regulatory axis that controls hepatic stellate cell survival during fibrosis. The work shows that curcumol promotes HUWE1-dependent HK2 degradation, activates RIPK1/RIPK3/MLKL signaling, and suppresses fibrosis through necroptotic elimination of activated stellate cells.
-
Miltefosine Activates ERK in Leukopenia
2026-08-14
A 2025 study identifies Miltefosine as a candidate modulator of leukopenia by promoting neutrophil differentiation through the Ras/MEK/ERK cascade. By combining leukemia-derived cell models, an irradiation-induced mouse model, transcriptomics, network pharmacology, molecular docking, and pathway inhibition, the work connects improved myelopoiesis with ERK pathway activity while leaving important translational questions unresolved.
-
Mitochondrial CAT-Tailing in Glioblastoma
2026-08-13
The reference study identifies mitochondrial stress-induced carboxyl-terminal alanine and threonine tailing as a ribosome-associated quality-control response that supports glioblastoma survival, migration, and growth. By linking CAT-tailed ATP synthase components to mitochondrial membrane potential, permeability transition, and apoptosis resistance, the work provides a mechanistic framework for studying proteostasis–metabolism interactions in glioblastoma.
-
BH3-Mimetics Reveal GBM’s Apoptotic Vulnerability
2026-08-13
Koessinger and colleagues show that glioblastoma, including stem-like tumor cells, depends on elevated anti-apoptotic BCL-xL and MCL-1 activity. Their preclinical data indicate that sequential targeting of these BCL-2 family proteins can produce strong antitumor responses without overt toxicity in the tested models.
-
CX-5461: A Mechanism-Led Cancer Assay Guide
2026-08-12
Explore how CX-5461, an RNA polymerase I inhibitor, connects rRNA suppression with DNA damage, mitotic catastrophe, senescence, and autophagy. This assay-focused guide translates current cervical cancer findings into practical experimental design decisions.
-
Computational Hapten Design for Dual Toxin Detection
2026-08-12
This 2026 study combines molecular similarity analysis, quantum-chemical calculations, and monoclonal antibody development to improve the simultaneous recognition of amatoxins and phallotoxins. Its dual-target fluorescent immunochromatographic assay translates that design strategy into sensitive mushroom testing, while also clarifying the distinction between toxin detection and mechanistic β-amanitin experiments.
-
SAR131675: Designing VEGFR-3 Mechanism Studies
2026-08-11
Explore how SAR131675, a selective VEGFR-3 inhibitor, can separate receptor-specific lymphatic biology from broader vascular and renal injury pathways. This article translates its biochemical and cellular profile into assay decisions informed by nicotine-associated chronic kidney disease research.